PAH Treatment

Introduction: Combination Therapy in the Treatment of PAH

3 Major Pathways Depicting the Pathophysiology of PAH

Different Agents Target Different Vasomotor Pathways in PAH

Combination Pharmacotherapy in PAH: Rationale and Potential Clinical Benefits

Complementary Pathways for the Treatment of PAH

Significantly Reduced Outcomes Significantly Reduced Outcomes* With Monotherapy vs Combination Therapy†

Combination Therapy Trials for the Treatment of PAH: A Summary

Different Combination Strategies for the Treatment of PAH

Initial/Upfront Use of Combination Therapy in PAH: The AMBITION Trial

Different Combination Strategies for the Treatment of PAH (cont)

AMBITION*: Significant Improvement in Outcomes With Initial Ambrisentan + Tadalafil

PATENT-1*: Significant Improvement In Exercise Capacity With Add-On Riociguat

SERAPHIN*: Significant Improvement in Outcomes With Add-On Macitentan

COMPASS-2*: Adding Bosentan to Stable Sildenafil Did Not Delay Time to First Morbidity/Mortality Event

Sildenafil + Bosentan: A Combination to Avoid?

Safety and Efficacy of Sildenafil When Added on to Bosentan

ERS/ESC Evidence-Based Treatment Algorithm for Patients With PAH

ESC/ERS Recommendations for Sequential Drug Combination Therapy for PAH

ESC/ERS Recommendations for Initial Combination Therapy*

Evidence-Based Combination Therapy for PAH Treatment

Case Example: 51-Year-Old Woman With IPAH

PAH Treatment

18 Months Later

Case Take-Home Points

Practical Guidance Regarding Combination Therapy

Risk Assessment in Patients With PAH

Concluding Remarks